fbpx

Eli Lilly to target cancer drug developers for deals

Eli Lilly to target cancer drug developers for deals

(Reuters) – Eli Lilly and Co will target cancer drug developers for deals, Chief Executive Officer Dave Ricks said on a post-earnings conference call on Wednesday.

“Probably because of the number of opportunities, you will see us active in oncology – that’s where a lot of early stage biotech is,” Ricks said.

OCTOBER 23, 2019

https://www.reuters.com/

Share this:
October 23, 2019 / Pharma News